Phase 3 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with high-risk or borderline resectable pancreatic cancer, confirmed through a tissue or cell sample test
- People aged 18 to 75 years old (inclusive)
- People who do not carry mutations in the BRCA1, BRCA2, or PALB2 genes
- People who have not previously had surgery, drug treatment, or radiation therapy for pancreatic cancer
- People with a good general level of physical functioning, rated 0 or 1 on a standard oncology scale (ECOG scale)
- People with a life expectancy of at least 6 months
- People who have at least one tumour that can be measured using standard imaging criteria (RECIST v1.1)
- People whose organs and bone marrow are functioning at adequate levels
- Women who are able to become pregnant and are willing to use effective contraception during the trial
Who may not be able to join:
- People whose cancer has spread to distant parts of the body
- People who have received a blood transfusion, blood products, or blood-boosting medications (such as albumin or G-CSF) within the 14 days before joining
- People who have had surgery or another invasive procedure within 4 weeks before joining (minor procedures such as a venous catheter, needle biopsy, or drainage may be exceptions — confirm with trial site)
- People with a known allergy to the study drug or any of its ingredients
- People with electrolyte (blood mineral) abnormalities considered clinically significant by the trial doctors
- People with a history of serious heart or stroke-related conditions
- People with an active stomach or intestinal ulcer, a hole in the intestine, or a bowel blockage
- People with uncontrolled fluid build-up in the abdomen (ascites) that cannot be managed with water tablets or drainage
- People with active bleeding or a clear tendency to bleed
- People with high blood pressure that cannot be controlled with medication (systolic at or above 150 mmHg and/or diastolic at or above 100 mmHg)
- Women who are pregnant or breastfeeding
- People with significant amounts of protein detected in their urine (at or above a certain threshold on testing)
- People who have had another cancer diagnosis within the past 5 years, with the exception of certain treated early-stage cancers such as cervical carcinoma in situ or basal cell skin cancer
- People who have difficulty swallowing or absorbing oral medications, or who are unable to take medications by mouth
- People with a known HIV infection
- People with significant liver disease, including active hepatitis B or C infection with detectable virus levels, or cirrhosis
- People who have any other medical condition, abnormal test result, or other circumstance that the trial doctors consider would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jihui Hao, M.D., Tianjin Medical University Cancer Institute and Hospital
Phone: 022-23524155
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Surgical complete resection rate (R0)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.